Last reviewed · How we verify
treatment with dorzolamide/timolol
treatment with dorzolamide/timolol is a Carbonic anhydrase inhibitor / Beta-blocker combination Small molecule drug developed by Aristotle University Of Thessaloniki. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension.
Dorzolamide/timolol is a fixed-dose combination that reduces intraocular pressure by inhibiting carbonic anhydrase (dorzolamide) and blocking beta-adrenergic receptors (timolol).
Dorzolamide/timolol is a fixed-dose combination that reduces intraocular pressure by inhibiting carbonic anhydrase (dorzolamide) and blocking beta-adrenergic receptors (timolol). Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | treatment with dorzolamide/timolol |
|---|---|
| Sponsor | Aristotle University Of Thessaloniki |
| Drug class | Carbonic anhydrase inhibitor / Beta-blocker combination |
| Target | Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dorzolamide decreases aqueous humor production by inhibiting carbonic anhydrase II in the ciliary body, while timolol reduces aqueous humor production and increases uveoscleral outflow through non-selective beta-adrenergic receptor antagonism. Together, these complementary mechanisms provide additive intraocular pressure reduction.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular burning or stinging
- Blurred vision
- Tearing
- Headache
- Bitter taste
- Allergic conjunctivitis
Key clinical trials
- Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (PHASE3)
- Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL (PHASE3)
- From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy (NA)
- Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema (PHASE2, PHASE3)
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- treatment with dorzolamide/timolol CI brief — competitive landscape report
- treatment with dorzolamide/timolol updates RSS · CI watch RSS
- Aristotle University Of Thessaloniki portfolio CI
Frequently asked questions about treatment with dorzolamide/timolol
What is treatment with dorzolamide/timolol?
How does treatment with dorzolamide/timolol work?
What is treatment with dorzolamide/timolol used for?
Who makes treatment with dorzolamide/timolol?
What drug class is treatment with dorzolamide/timolol in?
What development phase is treatment with dorzolamide/timolol in?
What are the side effects of treatment with dorzolamide/timolol?
What does treatment with dorzolamide/timolol target?
Related
- Drug class: All Carbonic anhydrase inhibitor / Beta-blocker combination drugs
- Target: All drugs targeting Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2)
- Manufacturer: Aristotle University Of Thessaloniki — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Compare: treatment with dorzolamide/timolol vs similar drugs
- Pricing: treatment with dorzolamide/timolol cost, discount & access